专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010033543A2 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS 审中-公开
标题翻译：新型化合物作为CANNABINOID受体配体
公开(公告)号：WO2010033543A2
公开(公告)日：2010-03-25
申请号：PCT/US2009/057088
申请日：2009-09-16
申请人： ABBOTT LABORATORIES , CARROLL, William A , DART, Michael J. , FROST, Jennifer M. , LATSHAW, Steven P. , KOLASA, Teodozyi , LI, Tongmei , PEDDI, Sridhar , LIU, Bo , PEREZ-MEDRANO, Arturo , PATEL, Meena , WANG, Xueqing , NELSON, Derek W.
发明人： CARROLL, William A , DART, Michael J. , FROST, Jennifer M. , LATSHAW, Steven P. , KOLASA, Teodozyi , LI, Tongmei , PEDDI, Sridhar , LIU, Bo , PEREZ-MEDRANO, Arturo , PATEL, Meena , WANG, Xueqing , NELSON, Derek W.
IPC分类号： C07D231/40 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14
CPC分类号： C07D405/12 , C07D231/40 , C07D285/135 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Disclosed herein are cannabinoid receptor ligands of formula (I), wherein A 1 , A 5 , R x , X 4 , and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
摘要翻译：本文公开了式（I）的大麻素受体配体，其中A1，A5，Rx，X4和z如说明书中所定义。还公开了包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

2. 发明申请

WO2010071783A1 THIAZOLES AS CANNABINOID RECEPTOR LIGANDS 审中-公开
标题翻译：作为CANNABINOID受体配体的THIAZOLES
公开(公告)号：WO2010071783A1
公开(公告)日：2010-06-24
申请号：PCT/US2009/068173
申请日：2009-12-16
申请人： ABBOTT LABORATORIES , FROST, Jennifer, M. , LATSHAW, Steven, P. , DART, Michael, J. , CARROLL, William, A. , PEREZ-MEDRANO, Arturo , KOLASA, Teodozyj , PATEL, Meena , NELSON, Derek, W. , LI, Tongmei , PEDDI, Sridhar , WANG, Xueqing , LUI, Bo
发明人： FROST, Jennifer, M. , LATSHAW, Steven, P. , DART, Michael, J. , CARROLL, William, A. , PEREZ-MEDRANO, Arturo , KOLASA, Teodozyj , PATEL, Meena , NELSON, Derek, W. , LI, Tongmei , PEDDI, Sridhar , WANG, Xueqing , LUI, Bo
IPC分类号： C07D277/46 , C07D417/12 , C07D513/04 , A61K31/426 , A61K31/427 , A61K31/428 , A61P3/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P29/00 , A61P35/00
CPC分类号： C07D417/12 , C07D277/46 , C07D513/04
摘要： Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L 1 , A 1 , R 1g , z, R 2 , R 3 , and R 4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
摘要翻译：本文公开了式（I）的大麻素受体配体，其中L1，A1，R1g，z，R2，R3和R4如说明书中所定义。还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。

3. 发明申请

WO2010028338A2 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS 审中-公开
标题翻译：新型化合物作为CANNABINOID受体配体
公开(公告)号：WO2010028338A2
公开(公告)日：2010-03-11
申请号：PCT/US2009/056179
申请日：2009-09-08
申请人： ABBOTT LABORATORIES , CARROLL, William, A. , DART, Michael, J. , FROST, Jennifer, M. , KOLASA, Teodozyj , LI, Tongmei , LIU, Bo , PEREZ-MEDRANO, Arturo , PATEL, Meena , WANG, Xueqing , PEDDI, Sridhar
发明人： CARROLL, William, A. , DART, Michael, J. , FROST, Jennifer, M. , KOLASA, Teodozyj , LI, Tongmei , LIU, Bo , PEREZ-MEDRANO, Arturo , PATEL, Meena , WANG, Xueqing , PEDDI, Sridhar
IPC分类号： C07D277/46 , C07D417/06 , C07D417/14 , A61K31/427 , A61P29/00
CPC分类号： C07D417/06 , C07D277/46 , C07D417/14
摘要： The present application relates to cannabinoid receptor ligands of formula (I), wherein X 1 , A 1 , R x , R 2 , R 3 , R 4 , and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.
摘要翻译：本申请涉及式（I）的大麻素受体配体，其中X1，A1，Rx，R2，R3，R4和z如说明书中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

4. 发明申请

WO2011075522A1 PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS 审中-公开
标题翻译： PRODRUG化合物作为CANNABINOID配体有用
公开(公告)号：WO2011075522A1
公开(公告)日：2011-06-23
申请号：PCT/US2010/060485
申请日：2010-12-15
申请人： ABBOTT LABORATORIES , NELSON, Derek , DART, Michael , WANG, Xueqing , LIU, Bo , KOLASA, Teodozyj , PATEL, Meena
发明人： NELSON, Derek , DART, Michael , WANG, Xueqing , LIU, Bo , KOLASA, Teodozyj , PATEL, Meena
IPC分类号： C07D513/04
CPC分类号： C07D513/04
摘要： The present invention provides for compounds of formula (I) wherein A 2 , L 2 , R 1g , R 2A , R 3A , R 4A , R 1a , R 1b , q1, and z are as defined in the specification, are prodrugs of CB 2 receptors ligands and as such are useful in the prevention and treatment of various diseases and conditions including, but not limited to, pain.
摘要翻译：本发明提供式（I）化合物，其中A2，L2，R1g，R2A，R3A，R4A，R1a，R1b，q1和z如本说明书中所定义，是CB2受体配体的前药，因此有用在预防和治疗各种疾病和病症，包括但不限于疼痛。

5. 发明申请

WO2012038980A3 FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST 审中-公开
公开(公告)号：WO2012038980A3
公开(公告)日：2012-03-29
申请号：PCT/IN2011/000657
申请日：2011-09-22
申请人： ADVINUS THERAPEUTICS LIMITED , BARAWKAR, Dinesh , BASU, Sujay , RAMDAS, Vidya , NAYKODI, Minakshi , PATEL, Meena , SHEJUL, Yogesh , THORAT, Sachin , PANMAND, Anil
发明人： BARAWKAR, Dinesh , BASU, Sujay , RAMDAS, Vidya , NAYKODI, Minakshi , PATEL, Meena , SHEJUL, Yogesh , THORAT, Sachin , PANMAND, Anil
IPC分类号： C07D487/14 , A61K31/519 , A61K31/52 , A61K31/522 , A61P25/16 , A61P25/28
摘要： The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

6. 发明申请

WO2010103547A2 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS 审中-公开
标题翻译：取代的氟化吡啶化合物
公开(公告)号：WO2010103547A2
公开(公告)日：2010-09-16
申请号：PCT/IN2010/000145
申请日：2010-03-12
申请人： ADVINUS THERAPEUTICS PRIVATE LIMITED , PALLE, Venkata , RAMDAS, Vidya , BARAWKAR, Dinesh , BASU, Sujay , KOUL, Summon , WAMAN, Yogesh , PATEL, Meena , PANMAND, Anil
发明人： PALLE, Venkata , RAMDAS, Vidya , BARAWKAR, Dinesh , BASU, Sujay , KOUL, Summon , WAMAN, Yogesh , PATEL, Meena , PANMAND, Anil
IPC分类号： C07D473/30
CPC分类号： C07D473/40 , A61K31/522 , A61K31/5377 , C07D473/06 , C07D473/18 , C07D473/30
摘要： The present invention discloses substituted fused pyrimidine compounds of formula I, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The present invention also provides provide the use of compounds of formula (II), or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, for the treatment of a pathological disease susceptible to improvement by antagonism of adenosine receptors. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.
摘要翻译：本发明公开了式I的取代的稠合嘧啶化合物，其互变异构体，多晶型物，立体异构体，前药，溶剂合物，药学上可接受的盐或含有它们的药物组合物以及治疗由腺苷受体（AR）活性介导的病症和疾病的方法。本发明还提供式（II）化合物或其互变异构体，多晶型物，立体异构体，前药，溶剂化物或其药学上可接受的盐在治疗易受腺苷受体拮抗作用改善的病理疾病中的用途。本发明的化合物可用于治疗，预防或抑制可能易受腺苷受体拮抗作用改善的疾病和病症，例如哮喘，慢性阻塞性肺病，血管生成，肺纤维化，肺气肿，过敏性疾病，炎症，再灌注损伤，心肌缺血，动脉粥样硬化，高血压，充血性心力衰竭，视网膜病变，糖尿病，肥胖，炎性胃肠道疾病和/或自身免疫性疾病。

7. 发明申请

WO2012035548A1 PURINE COMPOUNDS AS PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS, THEIR PROCESS AND MEDICINAL APPLICATIONS 审中-公开
标题翻译：作为A2B腺苷受体拮抗剂的原料的嘌呤化合物，其方法和药物应用
公开(公告)号：WO2012035548A1
公开(公告)日：2012-03-22
申请号：PCT/IN2011/000620
申请日：2011-09-09
申请人： ADVINUS THERAPEUTICS PRIVATE LIMITED , BARAWKAR, Dinesh , BASU, Sujay , RAMDAS, Vidya , PALLE, Venkata Poornapragnacharyulu , WAMAN, Yogesh , PATEL, Meena , PANMAND, Anil
发明人： BARAWKAR, Dinesh , BASU, Sujay , RAMDAS, Vidya , PALLE, Venkata Poornapragnacharyulu , WAMAN, Yogesh , PATEL, Meena , PANMAND, Anil
IPC分类号： C07D473/30 , C07F9/02 , C07F9/06 , A61K31/522 , A61P11/06
CPC分类号： A61K31/522 , A61K31/675 , A61K45/06 , C07D473/30 , C07F9/65616
摘要： The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. {Formulas should be inserted here} The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor. Such conditions include, but are not limited to, asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders including inflammatory bowel disease, sickle cell disease, and/or autoimmune diseases. and to their use in treating mammals for various disease states, such as gastrointestinal disorders, immunological disorders, hypersensitivity disorders, neurological disorders, and cardiovascular diseases due to both cellular hyperproliferation and apoptosis, and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
摘要翻译：本公开内容涉及式（I）或式（II）的嘌呤化合物或其互变异构体，多晶型物，立体异构体，溶剂合物或其药学上可接受的盐或含有它们的药物组合物以及将由其介导的病症和疾病作为治疗方法 A2B腺苷受体拮抗剂。 {这里应插入配方}本公开的化合物可用于治疗，预防或抑制可能通过腺苷A2B受体介导而改善的疾病和病症。这些病症包括但不限于哮喘，慢性阻塞性肺病，血管发生，肺纤维化，肺气肿，过敏性疾病，炎症，再灌注损伤，心肌缺血，动脉粥样硬化，高血压，充血性心力衰竭，视网膜病变，糖尿病，肥胖症，包括炎性肠病，镰状细胞病和/或自身免疫性疾病的炎症性胃肠道疾病。以及它们用于治疗各种疾病状态的哺乳动物，例如胃肠道疾病，免疫学障碍，超敏反应性障碍，神经障碍以及由于细胞过度增殖和凋亡引起的心血管疾病等。本公开还涉及制备这些化合物的方法以及含有它们的药物组合物。

8. 发明公开

EP2334646A2 SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS 审中-公开
标题翻译：取代苯甲酰胺ALS大麻素受体配体
公开(公告)号：EP2334646A2
公开(公告)日：2011-06-22
申请号：EP09792591.1
申请日：2009-09-16
申请人： Abbott Laboratories
发明人： CARROLL, William A , DART, Michael J. , FROST, Jennifer M. , LATSHAW, Steven P. , KOLASA, Teodozyj , LI, Tongmei , PEDDI, Sridhar , LIU, Bo , PEREZ-MEDRANO, Arturo , PATEL, Meena , WANG, Xueqing , NELSON, Derek W.
IPC分类号： C07D231/40 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14
CPC分类号： C07D405/12 , C07D231/40 , C07D285/135 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Disclosed herein are cannabinoid receptor ligands of formula (I), wherein A
1 , A
5 , R
x , X
4 , and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

9. 发明公开

EP2346843A2 SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS 审中-公开
标题翻译：取代苯甲酰胺ALS大麻素受体配体
公开(公告)号：EP2346843A2
公开(公告)日：2011-07-27
申请号：EP09792301.5
申请日：2009-09-08
申请人： Abbott Laboratories
发明人： CARROLL, William, A. , DART, Michael, J. , FROST, Jennifer, M. , KOLASA, Teodozyj , LI, Tongmei , LIU, Bo , PEREZ-MEDRANO, Arturo , PATEL, Meena , WANG, Xueqing , PEDDI, Sridhar
IPC分类号： C07D277/46 , C07D417/06 , C07D417/14 , A61K31/427 , A61P29/00
CPC分类号： C07D417/06 , C07D277/46 , C07D417/14
摘要： The present application relates to cannabinoid receptor ligands of formula (I), wherein X
1 , A
1 , R
x , R
2 , R
3 , R
4 , and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

10. 发明公开

EP2376462A1 Thiazoles as cannabinoid receptor ligands 有权
标题翻译：噻唑ALS大麻素受体配体
公开(公告)号：EP2376462A1
公开(公告)日：2011-10-19
申请号：EP09775056.6
申请日：2009-12-16
申请人： Abbott Laboratories
发明人： FROST, Jennifer, M. , LATSHAW, Steven, P. , DART, Michael, J. , CARROLL, William, A. , PEREZ-MEDRANO, Arturo , KOLASA, Teodozyj , PATEL, Meena , NELSON, Derek, W. , LI, Tongmei , PEDDI, Sridhar , WANG, Xueqing , LIU, Bo
IPC分类号： C07D277/46 , C07D417/12 , C07D513/04 , A61K31/426 , A61K31/427 , A61K31/428 , A61P3/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P29/00 , A61P35/00
CPC分类号： C07D417/12 , C07D277/46 , C07D513/04
摘要： Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L
1 , A
1 , R
1g , z, R
2 , R
3 , and R
4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式